CN118176188A - 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用 - Google Patents

一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用 Download PDF

Info

Publication number
CN118176188A
CN118176188A CN202280074508.9A CN202280074508A CN118176188A CN 118176188 A CN118176188 A CN 118176188A CN 202280074508 A CN202280074508 A CN 202280074508A CN 118176188 A CN118176188 A CN 118176188A
Authority
CN
China
Prior art keywords
ligand compound
psma
pharmaceutically acceptable
integer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280074508.9A
Other languages
English (en)
Chinese (zh)
Inventor
钟志远
袁建栋
杨江涛
皇甫贞元
孙娟
徐斌
陶蕾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Xingrui Jingxuan Biotechnology Co ltd
Original Assignee
Suzhou Ruihe Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Ruihe Pharmaceutical Technology Co ltd filed Critical Suzhou Ruihe Pharmaceutical Technology Co ltd
Publication of CN118176188A publication Critical patent/CN118176188A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280074508.9A 2021-11-10 2022-11-09 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用 Pending CN118176188A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111329108 2021-11-10
CN2021113291081 2021-11-10
PCT/CN2022/130833 WO2023083209A1 (zh) 2021-11-10 2022-11-09 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用

Publications (1)

Publication Number Publication Date
CN118176188A true CN118176188A (zh) 2024-06-11

Family

ID=86335105

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280074508.9A Pending CN118176188A (zh) 2021-11-10 2022-11-09 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用

Country Status (9)

Country Link
US (1) US20260069725A1 (https=)
EP (1) EP4431503A1 (https=)
JP (1) JP2024544870A (https=)
KR (1) KR20240105380A (https=)
CN (1) CN118176188A (https=)
AU (1) AU2022384375A1 (https=)
CA (1) CA3237743A1 (https=)
TW (1) TW202321204A (https=)
WO (1) WO2023083209A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002208A1 (zh) * 2024-06-28 2026-01-02 思路迪生物医药(上海)有限公司 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118852044A (zh) 2021-09-03 2024-10-29 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN117069670B (zh) * 2023-07-31 2026-04-10 复旦大学附属华山医院 靶向psma的二聚体化合物及其衍生物和应用
CN119954773A (zh) * 2023-10-31 2025-05-09 苏州威智创科生物有限公司 Psma化合物、包含其的药物组合物及其用途
WO2025167998A1 (zh) * 2024-02-06 2025-08-14 北京昌平实验室 膦酸酯骨架的psma靶向偶联物
CN118221764A (zh) * 2024-03-05 2024-06-21 苏州大学 一种双靶向分子探针及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629201B2 (en) * 2017-05-24 2023-04-18 ITM Isotope Technologies Munich SE PSMA-binding agents and uses thereof
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
CN114401947B (zh) * 2019-06-21 2024-11-29 省卫生服务机构 靶向前列腺特异性膜抗原的放射性标记化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002208A1 (zh) * 2024-06-28 2026-01-02 思路迪生物医药(上海)有限公司 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用

Also Published As

Publication number Publication date
JP2024544870A (ja) 2024-12-05
AU2022384375A1 (en) 2024-05-09
KR20240105380A (ko) 2024-07-05
EP4431503A1 (en) 2024-09-18
CA3237743A1 (en) 2023-05-19
TW202321204A (zh) 2023-06-01
US20260069725A1 (en) 2026-03-12
WO2023083209A1 (zh) 2023-05-19

Similar Documents

Publication Publication Date Title
CN118176188A (zh) 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用
CN102911256B (zh) 一种放射性标记的多肽配合物及其制备方法和应用
CN113004371A (zh) 一种长循环半衰期的前列腺特异性膜抗原靶向化合物及其制备方法和应用
EP0831938B1 (en) Radiolabeled peptide compositions for site-specific targeting
CN111905112A (zh) 靶向pd-l1的多肽复合物及其应用
CN116514735B (zh) 一种肽脲素衍生物、含其的药物组合物及其应用
CN110305186B (zh) 前列腺癌PET诊断试剂68Ga-DOTA-ANCP-PSMA及其制备方法和应用
CN118955478B (zh) 谷氨酸尿素类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物
CN112043839A (zh) 靶向转铁蛋白受体的放射性同位素标记多肽显像剂及其应用
CN115745903B (zh) 一种肽脲素衍生物、含其的药物组合物及其应用
TWI893724B (zh) 丹磺醯胺修飾的psma靶向化合物及其製備方法和應用
CN107308466B (zh) 具有肿瘤血管靶向性的多肽、分子探针及其制备方法和应用
JP7805170B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
CN116284236B (zh) 一种18f核素标记的生长抑素受体抑制剂探针及其制备方法和试剂盒
CN118666964A (zh) 一种靶向肿瘤pd-l1的pet示踪剂、其标记前体、制备方法和应用
PL239934B1 (pl) Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty
CN119874628B (zh) 一种含氮化合物及其制备方法与用途
CN118307640B (zh) 一种pet显像剂前体、pet显像剂及其制备方法和应用
CN114685608B (zh) 含有三硫醚键的环肽化合物或其衍生物、其合成方法和应用
CN120349373A (zh) 一种含氮化合物及其制备方法与用途
CN120209080A (zh) 一种αvβ3和PD-L1的双靶点分子探针及其应用
CN118725026A (zh) 一类靶向肿瘤相关成纤维细胞激活蛋白的糖肽、放射性核素标记物及其应用
CN120022391A (zh) 靶向肿瘤pd-l1的放射性诊疗药物及其标记前体、制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20251017

Address after: 610219 Sichuan Province, Chengdu City, Chengdu Tianfu International Biomedical City (Building 9, No. 18, Second Section of Shengwu City Middle Road, Shuangliu District, 101, 201, 301)

Applicant after: Chengdu Xingrui Jingxuan Biotechnology Co.,Ltd.

Country or region after: China

Address before: 215000 Jiangsu Province Suzhou City China (Jiangsu) Free Trade Zone Suzhou Division of Suzhou Industrial Park Xinping Street 388 Building 23 3rd Floor Unit 05, 06 Area B No. 25

Applicant before: Suzhou Ruihe Pharmaceutical Technology Co.,Ltd.

Country or region before: China